Study to Assess the Effect of Rifampicin (CYP Inducer) on Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours

NCT01929603 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumours

Interventions

PROCEDURE: Pharmacokinetic sampling
DRUG: Rifampicin
DRUG: Olaparib tablet dosing

Sponsor

AstraZeneca